Genfit (GNFT) Corporate presentation summary

Corporate overview and financial highlights

• Over 25 years of experience in liver diseases, advancing assets from discovery to commercialization.

• Focus on rare, severe liver diseases with high unmet medical need and a cash position of €136.1M as of 1Q26, with a cash runway beyond 2028 and no debt overhang.

• Strategic partnership with Ipsen for elafibranor, including €120M upfront, up to €360M in milestones, and tiered royalties up to 20%.

• Ipsen doubled peak sales estimates for Iqirvo (elafibranor) in PBC from €500M to €1bn.

• Royalty deal with HCRX provided €160M in non-dilutive funding.

Elafibranor (Iqirvo) commercial and clinical progress

• Iqirvo launched in 2024 for PBC, with cumulative milestone payments of €105.5M and €34M in royalties received to date.

• Ipsen’s ELSPIRE Phase IIIb study showed 85% ALP normalization in PBC patients, expanding the addressable market.

• Ongoing global Phase 3 trial in PSC, a disease with no approved therapies and a substantial untapped market.

• Additional milestone and royalty opportunities tied to PSC approval and commercialization.

Non-invasive diagnostics for MASH

• NASHnext test, based on GENFIT’s technology, will be reimbursed by Medicare from August 2026, supporting broader adoption.

• Diagnostic technology recognized by leading consortia (LITMUS, NIMBLE) and included in international clinical guidelines.

• Large-scale commercial rollout planned via Labcorp’s OnDemand platform.